A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability,
safety and pharmacokinetic characteristics of human chorionic gonadotropin between two
recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy
subjects. The subjects will injected with these two injections at the the 21day-interval of
time and their conditions including vital signs, blood, clinical examination will be
carefully observed.